No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
40 – 80
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Emory University · Other
Who this trial is looking for
This trial is looking for people with certain stages of chronic kidney disease who want to see if mindfulness meditation can help improve their health. Participants will also receive a type of nerve stimulation during the meditation.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with stage III or IV chronic kidney disease.
My kidney function has been stable for the last 3 months.
You may not be able to join if
I have severe chronic kidney disease with very low kidney function.
I have diabetic neuropathy.
I have any disease that could affect my survival.
I have been diagnosed with anemia.
I have had a heart attack or stroke in the past 6 months.
I have uncontrolled high blood pressure.
I have low blood pressure.
I am currently abusing drugs or alcohol.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* stages III and IV CKD as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation
* stable renal function (no greater than a decline of eGFR of 1 cc/min/1.73 m2 per month over the prior 3 months)
Exclusion Criteria:
* severe CKD (eGFR\<1…
Inclusion Criteria:
* stages III and IV CKD as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation
* stable renal function (no greater than a decline of eGFR of 1 cc/min/1.73 m2 per month over the prior 3 months)
Exclusion Criteria:
* severe CKD (eGFR\<15 cc/min)
* diabetic neuropathy
* autonomic dysfunction
* any serious disease that might influence survival
* anemia with hemoglobin \<10 g/dL
* treatment with central α-agonists or monoamine oxidase (MAO) inhibitors
* myocardial infarction or cerebrovascular accident within the past 6 months
* uncontrolled hypertension (BP≥170/100 mm Hg)
* low BP (BP\<100/50 mm Hg)
* bradycardia (HR\<55 beats/min)
* ongoing drug or alcohol abuse (defined as \>2 drinks/day in men, and \>1 drink/day in women)
* surgery within the past 3 months
* adjustment of antihypertensive medications within the past month
* pregnancy or plans to become pregnant
* psychosis
* suicidal ideation
* implanted electronic or metallic device such as a pacemaker
* implanted hearing aid, bone plate, carotid stent, bone screw at or near the neck
* carotid atherosclerosis
* concurrent use of another stimulating device such as a transcutaneous electrical nerve stimulation (TENS) unit
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
